News
AMLX
3.500
-7.16%
-0.270
Amylyx Pharmaceuticals Prices Offering Of Approx. 17.1 Mln Shares At $3.50 Per Share
NASDAQ · 1d ago
Amylyx stock dips after pricing $60M stock offering
Seeking Alpha · 1d ago
Amylyx Prices $60M Public Offering Of 17.1M Shares At A Price Of $3.50 Each
Benzinga · 1d ago
AMYLYX PHARMACEUTICALS INC - GROSS PROCEEDS EXPECTED TO BE APPROXIMATELY $60 MILLION
Reuters · 1d ago
Amylyx announces common stock offering, no amount given
TipRanks · 2d ago
NervGen In Spotlight As It Approaches Clinical Proof Of Concept Readout For Spinal Cord Regeneration
Seeking Alpha · 2d ago
Amylyx Pharmaceuticals Announces Pricing of Public Offering of Common Stock
Barchart · 2d ago
Amylyx Pharmaceuticals down 3%, announces stock offering
Seeking Alpha · 2d ago
Reported Earlier, Amylyx Pharmaceuticals Launches Public Offering Of Common Stock, Aims To Advance Pipeline And Operations
Benzinga · 2d ago
Amylyx Pharma Commences Underwritten Public Offering Of Shares
NASDAQ · 2d ago
*Amylyx Pharmaceuticals: Funds for Commercialization and Pipeline Programs, Working Capital, General Corporate Purposes >AMLX
Dow Jones · 2d ago
*Amylyx Pharmaceuticals: All of Shares Being Offered by Amylyx >AMLX
Dow Jones · 2d ago
*Amylyx Pharmaceuticals: Commenced Underwritten Public Offering of Shares of Its Common Stock >AMLX
Dow Jones · 2d ago
AMYLYX PHARMACEUTICALS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK
Reuters · 2d ago
AMYLYX PHARMACEUTICALS APPOINTS DAN MONAHAN AS CHIEF COMMERCIAL OFFICER
Reuters · 5d ago
Weekly Report: what happened at AMLX last week (1230-0103)?
Weekly Report · 6d ago
Gubra and Amylyx team on novel long-acting GLP-1 receptor antagonist development
TipRanks · 12/30/2024 19:00
Amylyx Partners with Gubra for GLP-1 Antagonist
TipRanks · 12/30/2024 13:18
Amylyx and Gubra Join Forces for Peptide Drug Discovery Collaboration
Benzinga · 12/30/2024 12:34
Weekly Report: what happened at AMLX last week (1223-1227)?
Weekly Report · 12/30/2024 09:22
More
Webull provides a variety of real-time AMLX stock news. You can receive the latest news about Amylyx Pharmaceuticals through multiple platforms. This information may help you make smarter investment decisions.
About AMLX
Amylyx Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is engaged in the discovery and development of treatments for neurodegenerative diseases. The Company is focused on the development and commercialization of its product candidate: AMX0035 for the treatment of Wolfram syndrome and for the treatment of progressive supranuclear palsy, and AMX0114, the Company’s antisense oligonucleotide targeting calpain-2 for the treatment of amyotrophic lateral sclerosis (ALS). AMX0035 is a dual-unfolded protein response (UPR)-Bax apoptosis inhibitor composed of PB and TURSO (also known as TUDCA). The Company’s Avexitide is an investigational, first-in-class glucagon-like peptide-1 (GLP-1) receptor antagonist that has been evaluated in five clinical trials for post-bariatric hypoglycemia (PBH) and has also been studied in congenital hyperinsulinism (HI), two indications characterized by hyperinsulinemic hypoglycemia.